Needham maintains Revance Therapeutics [RVNC] at Buy rating with a $45 price target
Needham maintained its Revance Therapeutics [RVNC] rating to the equivalent of Buy but changed the price target to $45.0 from $42, in a research note dated 2021-01-08. That figure represents around a 52.08% premium from where the company’s shares closed on Thursday. Meanwhile, Goldman had lowered its rating on RVNC to “Neutral” from the earlier […]
